Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2010
11/11/2010US20100284905 Methods and Agents for Inhibiting Tumor Growth by Targeting the SSDNA Replication Intermediate of Tumor Stem Cells
11/11/2010US20100282622 Solid formulations of prostacyclin analogs
11/11/2010US20100282409 Antimicrobial compositions
11/11/2010DE202010012256U1 Abführmittel Laxative
11/11/2010DE202010012099U1 Vitaminzusammensetzung und Darreichungsform umfassend Vitamin D3 geeignet für die Osteoporoseprophylaxe und/oder Behandlung A vitamin composition and dosage form comprising Vitamin D3 suitable for osteoporosis prophylaxis and / or treatment
11/11/2010DE202010012043U1 Vorrichtung zur Dosierung einer säurehaltigen Zusammensetzung A device for metering an acidic composition
11/11/2010DE102009019962A1 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate 3 - ([1,2,3] triazol-4-yl) pyrrolo [2,3-b] pyridine
11/11/2010DE102009019322A1 Verfahren zur Herstellung von Synthetischen Cannabinoiden A process for the production of synthetic cannabinoids
11/11/2010CA2821174A1 A method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
11/11/2010CA2799157A1 Ammo acid derivatives for the treatment of neuropathic pain
11/11/2010CA2764232A1 Novel heterocyclic compounds
11/11/2010CA2761248A1 Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
11/11/2010CA2761182A1 Pyrrolidine-substituted flavones as radio-sensitizers for use in the treatment of cancer
11/11/2010CA2761156A1 Methods of preventing ischemic injury using peripheral nociceptive stimulation
11/11/2010CA2761152A1 Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
11/11/2010CA2761150A1 Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans
11/11/2010CA2761146A1 Antitumor combination including ave8062 and sorafenib
11/11/2010CA2761142A1 Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
11/11/2010CA2761130A1 Anti-inflammatory agents as virostatic compounds
11/11/2010CA2761079A1 Antitumor combination including cabazitaxel and capecitabine
11/11/2010CA2761061A1 Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof
11/11/2010CA2761032A1 Phenoxymethyl heterocyclic compounds
11/11/2010CA2761018A1 Substituted aromatic compounds and pharmaceutical uses thereof
11/11/2010CA2761009A1 Compounds and methods for inhibition of renin, and indications therefor
11/11/2010CA2761000A1 Composition for sustained drug delivery comprising geopolymeric binder
11/11/2010CA2760953A1 Triptolide prodrugs
11/11/2010CA2760929A1 Pmk2 modulators for use in the treatment of cancer
11/11/2010CA2760883A1 Prevention and treatment of nosema disease in bees
11/11/2010CA2760877A1 Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
11/11/2010CA2760844A1 3-(1,2,3-triazol-4-yl)pyrrolo[2,3-b]pyridine derivatives
11/11/2010CA2760794A1 Egfr inhibitors and methods of treating disorders
11/11/2010CA2760786A1 Use of pde7 inhibitors for the treatment of movement disorders
11/11/2010CA2760746A1 Isoxazole-pyrazole derivatives
11/11/2010CA2760705A1 Pyrazolopyridines
11/11/2010CA2760575A1 Topical compositions comprising inorganic particulates and an alkoxylated diphenylacrylate compound
11/11/2010CA2760555A1 Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine
11/11/2010CA2760535A1 Vinyl indazolyl compounds
11/11/2010CA2760499A1 Solid formulations of prostacyclin analogs
11/11/2010CA2760464A1 Carboxamide compounds and their use as calpain inhibitors
11/11/2010CA2760450A1 Topical compositions comprising an alkoxylated diphenylacrylate compound and an aryl carboxylic ester
11/11/2010CA2760343A1 Dihydropyrimidinones for use as bace2 inhibitors
11/11/2010CA2760339A1 Novel isoquinoline derivatives
11/11/2010CA2760166A1 Isoxazole-pyridine derivatives
11/11/2010CA2760159A1 Methods of treating bacterial infections using oritavancin
11/11/2010CA2760106A1 Inhibitors of sialidase or sialidase-like enzymes
11/11/2010CA2760061A1 Diamino heterocyclic carboxamide compound
11/11/2010CA2759997A1 Pyrrolo [2, 3. b] pyridines which inhibit raf protein kinase
11/11/2010CA2759951A1 Substituted phenylureas and phenylamides as vanilloid receptor ligands
11/11/2010CA2759891A1 Gpr 119 modulators
11/11/2010CA2759651A1 Substituted spirocyclic amines useful as antidiabetic compounds
11/11/2010CA2759598A1 Isoxazole-thiazole derivatives as gaba a receptor inverse agonists for use in the treatment of cognitive disorders
11/11/2010CA2759581A1 Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
11/11/2010CA2759399A1 Inhibitors of the renal outer medullary potassium channel
11/11/2010CA2759269A1 P38 kinase inhibiting agents
11/11/2010CA2759190A1 Pesticidal compositions
11/11/2010CA2758302A1 Compounds and compositions comprising cdk inhibitors and methods for treatment of cancer
11/11/2010CA2758289A1 Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands
11/11/2010CA2757412A1 Isoxazole-pyridine derivatives as gaba modulators
11/11/2010CA2757075A1 Nematocidal sulfonamides
11/11/2010CA2756689A1 Treatment of osteoarthritis pain
11/11/2010CA2725972A1 Paeoniflorin preparations and uses thereof for fat reduction
11/10/2010EP2248901A1 Streptogramines and method for preparing same by mutasynthesis
11/10/2010EP2248898A2 Methods for inducing differentiation of undifferentiated mammalian cells into osteoblasts
11/10/2010EP2248897A2 Methods for inducing differentiation of undifferentiated mammalian cells into osteoblasts
11/10/2010EP2248896A2 Methods for inducing differentiation of undifferentiated mammalian cells into osteoblasts
11/10/2010EP2248895A2 Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent
11/10/2010EP2248836A2 Prepolymer for biomedical materials
11/10/2010EP2248832A1 A g-csf conjugate modified by water-soluble polymer
11/10/2010EP2248829A1 Treatment with anti-VEGF antibodies
11/10/2010EP2248817A2 Substituted 2-amino-3-sulfonyl-pyrazolo[1,5-a] pyrimidines/antagonists of serotonin 5-ht6 receptors, methods for the production and the use thereof
11/10/2010EP2248816A2 2-ALKYLAMINO-3-ARYLSULFONYL-CYCLOALCANO [e OR ] PYRAZOLO [1,5-A] PYRIMIDINES / ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, METHODS FOR THE PRODUCTION AND THE USE THEREOF
11/10/2010EP2248815A2 3-sulfonyl-pyrazolo[1,5-a]pyrimidines / antagonists of serotonin 5-ht6 receptors, methods for the production and the use thereof
11/10/2010EP2248814A2 SUBSTITUTED CYCLOALCANO[e AND d] PYRAZOLO [1,5-a] PYRIMIDINES/ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS AND METHODS FOR PRODUCTION AND THE USE THEREOF
11/10/2010EP2248813A1 Production method and production device for composition having high content of theobromine
11/10/2010EP2248812A2 Fused cyclic compounds as GPR40 receptor modulators
11/10/2010EP2248811A1 2-oxochromene derivative
11/10/2010EP2248808A1 Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder
11/10/2010EP2248807A1 N-phenyl-2-pyrimidine-amine derivatives
11/10/2010EP2248806A2 Quinazoline derivatives as tyrosine kinase inhibitors
11/10/2010EP2248805A2 Method of synthesis of bosentan, its polymorphic forms and its salts
11/10/2010EP2248804A1 Combined use of angiogenesis inhibitor and taxane
11/10/2010EP2248801A1 Inhibitors of cytosolic phospholipase a2
11/10/2010EP2248798A1 Novel lipid compounds
11/10/2010EP2248796A1 2-methylene-5-substituted methylene cyclopentanone derivatives and use thereof
11/10/2010EP2248537A1 Restoration of cancer-suppressing functions to neoplastic cells through DNA hypomethylation
11/10/2010EP2248524A2 Preventives/remedies for stress urinary incontinence and method of screening the same
11/10/2010EP2248523A1 Compounds for use in the treatment of clinical conditions resulting from a deficit of endothelial progenitor cells
11/10/2010EP2248522A1 Immunosuppressive macrolide powder for oral suspension
11/10/2010EP2248521A1 Inhibitors of jun n-terminal kinases for treating glaucomatous retinopathy and ocular diseases
11/10/2010EP2248520A2 Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
11/10/2010EP2248519A2 Non-mucoadhesive film dosage forms
11/10/2010EP2248517A1 Concentrated mast cell stabilizing pharmaceutical formulations
11/10/2010EP2248516A1 Orally disintegrating compositions of emoxypine
11/10/2010EP2247612A1 Siva 3, its preparation and use
11/10/2010EP2247602A2 Adamantyl o-glucuronide derivatives as inhibitors of dipeptidyl peptidase iv for the treatment of diabetes
11/10/2010EP2247601A1 Thiazopyrimidinones and uses thereof
11/10/2010EP2247600A2 Benzoxazole carboxamide inhibitors of poly(adp-ribose)polymerase (parp)
11/10/2010EP2247599A1 Substituted arylamide oxazepinopyrimidone derivatives
11/10/2010EP2247598A1 Substituted heteroarylamide oxazepinopyrimidone derivatives
11/10/2010EP2247597A1 Fused heteroaryl modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof
1 ... 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 ... 7860